Ravi Salgia to Neoplasms
This is a "connection" page, showing publications Ravi Salgia has written about Neoplasms.
Connection Strength
6.221
-
Addressing the genetic/nongenetic duality in cancer with systems biology. Trends Cancer. 2023 03; 9(3):185-187.
Score: 0.309
-
Precision oncology provides opportunities for targeting KRAS-inhibitor resistance. Trends Cancer. 2023 01; 9(1):42-54.
Score: 0.305
-
RLIP: A necessary transporter protein for translating oxidative stress into pro-obesity and pro-carcinogenic signaling. Biochim Biophys Acta Rev Cancer. 2022 09; 1877(5):188803.
Score: 0.302
-
Quantifying Cancer: More Than Just a Numbers Game. Trends Cancer. 2021 04; 7(4):267-269.
Score: 0.271
-
Activating p53 function by targeting RLIP. Biochim Biophys Acta Rev Cancer. 2021 04; 1875(2):188512.
Score: 0.269
-
MET receptor in oncology: From biomarker to therapeutic target. Adv Cancer Res. 2020; 147:259-301.
Score: 0.259
-
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. Future Oncol. 2020 Jan; 16(1):4289-4301.
Score: 0.249
-
The Mitochondrion as an Emerging Therapeutic Target in Cancer. Trends Mol Med. 2020 01; 26(1):119-134.
Score: 0.243
-
Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy. BMC Cancer. 2018 03 21; 18(1):314.
Score: 0.221
-
The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer. Trends Cancer. 2018 02; 4(2):110-118.
Score: 0.219
-
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018 01 23; 6(1):8.
Score: 0.219
-
Value-Based Medicine and Integration of Tumor Biology. Am Soc Clin Oncol Educ Book. 2017; 37:833-840.
Score: 0.204
-
C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype. Cancer Biol Ther. 2016; 17(1):91-103.
Score: 0.190
-
Tumor Heterogeneity and Therapeutic Resistance. Am Soc Clin Oncol Educ Book. 2016; 35:e585-93.
Score: 0.190
-
MET as a drug target. Clin Adv Hematol Oncol. 2015 Jun; 13(6):351-3.
Score: 0.182
-
Molecular pathways and therapeutic targets in lung cancer. Oncotarget. 2014 Mar 30; 5(6):1392-433.
Score: 0.168
-
Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15; 20(6):1666-75.
Score: 0.166
-
Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor. J Thorac Oncol. 2012 Dec; 7(16 Suppl 5):S372-4.
Score: 0.153
-
MET pathway as a therapeutic target. J Thorac Oncol. 2009 Apr; 4(4):444-7.
Score: 0.119
-
Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer. 2008 Dec; 47(12):1025-37.
Score: 0.116
-
Review of clinic trials: agents targeting c-Met. Rev Recent Clin Trials. 2007 May; 2(2):143-7.
Score: 0.104
-
c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr Oncol Rep. 2007 Mar; 9(2):102-8.
Score: 0.103
-
Tyrosine kinase mutations in human cancer. Curr Mol Med. 2007 Feb; 7(1):77-84.
Score: 0.102
-
The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev. 2004 Dec; 15(6):419-33.
Score: 0.088
-
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005 Jul 08; 225(1):1-26.
Score: 0.088
-
Targeting c-Kit mutations: basic science to novel therapies. Leuk Res. 2004 May; 28 Suppl 1:S11-20.
Score: 0.085
-
Therapeutic targeting of the receptor tyrosine kinase Met. Cancer Treat Res. 2004; 119:121-38.
Score: 0.083
-
c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003 Dec; 22(4):309-25.
Score: 0.082
-
Radiation Sensitivity: The Rise of Predictive Patient-Derived Cancer Models. Semin Radiat Oncol. 2023 07; 33(3):279-286.
Score: 0.080
-
Prognostic significance of natural products against multidrug tumor resistance. Cancer Lett. 2023 03 31; 557:216079.
Score: 0.078
-
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev. 2002 Feb; 13(1):41-59.
Score: 0.072
-
Infectious complications of immune checkpoint inhibitors in solid organ malignancies. Cancer Med. 2022 01; 11(1):21-27.
Score: 0.072
-
MicroRNA-1: Diverse role of a small player in multiple cancers. Semin Cell Dev Biol. 2022 04; 124:114-126.
Score: 0.069
-
Group Behavior and Emergence of Cancer Drug Resistance. Trends Cancer. 2021 04; 7(4):323-334.
Score: 0.068
-
Therapeutic targeting of miRNA-216b in cancer. Cancer Lett. 2020 08 01; 484:16-28.
Score: 0.064
-
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors. Mol Cancer Ther. 2020 05; 19(5):1210-1217.
Score: 0.063
-
Role of the cytoskeletal protein paxillin in oncogenesis. Crit Rev Oncog. 2000; 11(1):63-76.
Score: 0.063
-
USP22 Interacts with PALB2 and Promotes Chemotherapy Resistance via Homologous Recombination of DNA Double-Strand Breaks. Mol Cancer Res. 2020 03; 18(3):424-435.
Score: 0.062
-
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317.
Score: 0.056
-
Untying the gordion knot of targeting MET in cancer. Cancer Treat Rev. 2018 May; 66:95-103.
Score: 0.056
-
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015 Aug; 5(8):850-9.
Score: 0.045
-
A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors. Mol Cancer Ther. 2015 Feb; 14(2):461-9.
Score: 0.044
-
Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clin Cancer Res. 2014 Dec 15; 20(24):6336-45.
Score: 0.044
-
Transactivation of the receptor-tyrosine kinase ephrin receptor A2 is required for the low molecular weight hyaluronan-mediated angiogenesis that is implicated in tumor progression. J Biol Chem. 2014 Aug 29; 289(35):24043-58.
Score: 0.043
-
Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol. 2014 Aug 01; 32(22):2328-34.
Score: 0.043
-
TLR3 agonists and proinflammatory antitumor activities. Expert Opin Ther Targets. 2013 May; 17(5):481-3.
Score: 0.039
-
PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab Invest. 2009 Mar; 89(3):301-14.
Score: 0.029
-
Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity. Clin Cancer Res. 2008 Jun 15; 14(12):3896-905.
Score: 0.028
-
Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications. J Clin Oncol. 1987 Dec; 5(12):1998-2003.
Score: 0.007
-
CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin. J Biol Chem. 2007 Oct 19; 282(42):30643-57.
Score: 0.007